Merck & Co Inc
MRK81.470USD
-4.900-5.67%
收盤 04/04, 16:00（美東）報價延遲15分鐘
205.93B總市值
12.03本益比TTM
關於 Merck & Co Inc 公司
默克公司是一家研究密集型生物製藥公司，致力於研究提供健康解決方案，促進人類和動物疾病的預防和治療。其製藥部門包括人類健康藥品和疫苗產品。人類健康藥品包括治療和預防藥物，通常通過處方出售，用於治療人類疾病。人類健康疫苗產品包括預防性兒童、青少年和成人疫苗。動物健康部門發現、開發、製造和銷售一系列獸藥和疫苗產品以及健康管理解決方案和服務，用於預防、治療和控制所有主要牲畜和伴侶動物物種的疾病。該公司還致力於開發一類新型小分子，以缺乏關鍵 DNA 修復蛋白 O6-甲基鳥嘌呤甲基轉移酶表達的癌細胞爲目標。
公司簡介
公司代碼MRK
公司名稱Merck & Co Inc
上市日期Jan 01, 1941
成立日期1970
CEOMr. Robert M. (Rob) Davis
員工數量75000
證券類型Ordinary Share
年結日Jan 01
公司地址2000 Galloping Hill Road
城市KENILWORTH
上市交易所NYSE Consolidated
國家United States of America
郵編07033
電話19087404000
網址https://www.merck.com/
公司代碼MRK
上市日期Jan 01, 1941
成立日期1970
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
+27.35%
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
78.86K
+70.54%
Ms. Caroline Litchfield
Ms. Caroline Litchfield
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
74.34K
+46.03%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
66.61K
+73.22%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
53.42K
+90.81%
Mr. Michael A. Klobuchar
Mr. Michael A. Klobuchar
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
23.22K
+1.98%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
20.72K
+5.86%
Ms. Patricia F. Russo
Ms. Patricia F. Russo
Independent Director
Independent Director
13.15K
--
Mr. Thomas Henry (Tom) Glocer, J.D.
Mr. Thomas Henry (Tom) Glocer, J.D.
Lead Independent Director
Lead Independent Director
5.10K
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
+27.35%
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
78.86K
+70.54%
Ms. Caroline Litchfield
Ms. Caroline Litchfield
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
74.34K
+46.03%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
66.61K
+73.22%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
53.42K
+90.81%
收入明細
單位: USD更新時間: 4 小時前
單位: USD更新時間: 4 小時前
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Oncology-Keytruda
29.48B
45.95%
Vaccines -Gardasil/Gardasil
8.58B
13.38%
Animal Health-Livestock
3.46B
5.39%
Other pharmaceutical
2.51B
3.91%
Vaccines -ProQuad/M-M-R II/Varivax
2.48B
3.87%
Other
17.65B
27.50%
地區USD
名稱
營收
佔比
United States
32.28B
50.30%
Europe, Middle East and Africa
14.04B
21.88%
China
5.49B
8.56%
Latin America
3.46B
5.39%
Japan
3.28B
5.11%
Other
5.62B
8.75%
業務
地區
業務USD
名稱
營收
佔比
Oncology-Keytruda
29.48B
45.95%
Vaccines -Gardasil/Gardasil
8.58B
13.38%
Animal Health-Livestock
3.46B
5.39%
Other pharmaceutical
2.51B
3.91%
Vaccines -ProQuad/M-M-R II/Varivax
2.48B
3.87%
Other
17.65B
27.50%
股東統計
更新時間: 3月11日 週二
更新時間: 3月11日 週二
持股股東
股東類型
持股股東
股東統計
佔比
The Vanguard Group, Inc.
10.03%
BlackRock Institutional Trust Company, N.A.
5.68%
State Street Global Advisors (US)
4.79%
Wellington Management Company, LLP
3.20%
Geode Capital Management, L.L.C.
2.42%
Other
73.89%
持股股東
股東統計
佔比
The Vanguard Group, Inc.
10.03%
BlackRock Institutional Trust Company, N.A.
5.68%
State Street Global Advisors (US)
4.79%
Wellington Management Company, LLP
3.20%
Geode Capital Management, L.L.C.
2.42%
Other
73.89%
股東類型
股東統計
佔比
Investment Advisor/Hedge Fund
35.88%
Investment Advisor
31.44%
Research Firm
3.76%
Pension Fund
2.96%
Bank and Trust
2.38%
Hedge Fund
1.52%
Sovereign Wealth Fund
1.49%
Insurance Company
0.69%
Family Office
0.11%
Other
19.77%
機構持股
更新時間: 2月20日 週四
更新時間: 2月20日 週四
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
5313
2.05B
81.05%
+16.08M
2024Q4
5410
2.04B
80.88%
+11.87M
2024Q3
5200
2.01B
79.47%
-7.96M
2024Q2
5181
2.01B
79.28%
-4.86M
2024Q1
5154
2.00B
78.88%
-6.10M
2023Q4
5065
1.99B
78.60%
+584.81K
2023Q3
4871
1.98B
78.17%
-32.03M
2023Q2
4864
2.00B
78.94%
-18.54M
2023Q1
4818
1.99B
78.43%
-16.95M
2022Q4
4785
1.98B
77.94%
-5.23M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
253.26M
10.03%
+3.27M
+1.31%
Feb 28, 2025
BlackRock Institutional Trust Company, N.A.
143.39M
5.68%
+10.26M
+7.71%
Dec 31, 2024
State Street Global Advisors (US)
120.91M
4.79%
+1.88M
+1.58%
Dec 31, 2024
Wellington Management Company, LLP
80.74M
3.2%
+4.93M
+6.51%
Dec 31, 2024
Geode Capital Management, L.L.C.
61.18M
2.42%
+2.03M
+3.43%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
34.98M
1.38%
+1.17M
+3.47%
Dec 31, 2024
Fidelity Management & Research Company LLC
33.58M
1.33%
-11.95M
-26.24%
Dec 31, 2024
BofA Global Research (US)
23.08M
0.91%
-1.38M
-5.65%
Dec 31, 2024
BlackRock Asset Management Ireland Limited
21.22M
0.84%
+1.34M
+6.77%
Dec 31, 2024
Morgan Stanley Smith Barney LLC
20.63M
0.82%
-290.99K
-1.39%
Dec 31, 2024
查看更多
持股ETF
更新時間: 16 小時前
更新時間: 16 小時前
機構名稱
佔比
FT Vest DJIA Dogs 10 Target Income ETF
11.99%
First Trust NASDAQ Pharmaceuticals ETF
6.57%
VanEck Pharmaceutical ETF
5.04%
TBG Dividend Focus ETF
4.77%
Amplify Weight Loss Drug & Treatment ETF
4.76%
Invesco Pharmaceuticals ETF
4.51%
VictoryShares Free Cash Flow ETF
4.51%
Tema Oncology ETF
4.49%
Vaneck Durable High Dividend ETF
4.48%
Proshares Ultra Health Care
4.26%
查看更多
FT Vest DJIA Dogs 10 Target Income ETF
佔比11.99%
First Trust NASDAQ Pharmaceuticals ETF
佔比6.57%
VanEck Pharmaceutical ETF
佔比5.04%
TBG Dividend Focus ETF
佔比4.77%
Amplify Weight Loss Drug & Treatment ETF
佔比4.76%
Invesco Pharmaceuticals ETF
佔比4.51%
VictoryShares Free Cash Flow ETF
佔比4.51%
Tema Oncology ETF
佔比4.49%
Vaneck Durable High Dividend ETF
佔比4.48%
Proshares Ultra Health Care
佔比4.26%
分紅派息
近5年累計派現
35.12B
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Jan 28, 2025
MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Apr 07, 2025 going ex on Mar 17, 2025
Mar 17, 2025
Apr 07, 2025
Mar 17, 2025
Nov 19, 2024
MRK.NB Final Cash Dividend of gross USD 0.81 paid on Jan 08, 2025 going ex on Dec 16, 2024
Dec 16, 2024
Jan 08, 2025
Dec 16, 2024
Jul 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Oct 07, 2024 going ex on Sep 16, 2024
Sep 16, 2024
Oct 07, 2024
Sep 16, 2024
May 29, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Jul 08, 2024 going ex on Jun 17, 2024
Jun 17, 2024
Jul 08, 2024
Jun 17, 2024
Jan 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Apr 05, 2024 going ex on Mar 14, 2024
Mar 15, 2024
Apr 05, 2024
Mar 14, 2024
Nov 28, 2023
MRK.NB Final Cash Dividend of gross USD 0.77 paid on Jan 08, 2024 going ex on Dec 14, 2023
Dec 15, 2023
Jan 08, 2024
Dec 14, 2023
Jul 25, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Oct 06, 2023 going ex on Sep 14, 2023
Sep 15, 2023
Oct 06, 2023
Sep 14, 2023
May 23, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Jul 10, 2023 going ex on Jun 14, 2023
Jun 15, 2023
Jul 10, 2023
Jun 14, 2023
Jan 24, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Apr 10, 2023 going ex on Mar 14, 2023
Mar 15, 2023
Apr 10, 2023
Mar 14, 2023
Nov 30, 2022
MRK.NB Final Cash Dividend of gross USD 0.73 paid on Jan 09, 2023 going ex on Dec 14, 2022
Dec 15, 2022
Jan 09, 2023
Dec 14, 2022
查看更多
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據